All canine diagnoses

Your dog was diagnosed with Perianal (Hepatoid) Adenocarcinoma. Hepatoid gland tumours are common in intact male dogs but ~90% are benign adenomas. Adenocarcinomas (malignant) are less common. Distinguished from anal sac apocrine gland adenocarcinoma — different tumour type. Testosterone-responsive (adenomas regress with castration; carcinomas do not). Compare 2 treatment options for dogs including Surgical Excision ± Castration, Palliation / Antihormonal Therapy — with survival times, costs, and what to expect during treatment.

🐕

Perianal (Hepatoid) Adenocarcinoma

BreedsCocker SpanielSiberian HuskyBeagleIntact males primarily for adenomas; carcinomas in both sexes
canine

Epithelial

About This Cancer

Perianal (hepatoid) adenocarcinoma is a malignant tumour arising from the hepatoid glands — specialised sebaceous glands found in the skin around the anus, so named because their cells resemble liver (hepatic) cells under the microscope. It is important to distinguish this malignant tumour from the far more common benign hepatoid adenoma, which occurs predominantly in intact male dogs and often regresses with castration. Unlike the benign form, hepatoid adenocarcinoma does not regress with castration and can occur in either sex. It also differs from anal sac apocrine gland adenocarcinoma, which is a distinct tumour type arising from a different gland. The malignant form can invade locally and spread to regional lymph nodes. Treatment is primarily surgical, and prognosis depends on the tumour size, grade, and whether complete excision is achieved.

No formal staging system

Clinically staged by tumour size, histological grade, LN status, and distant metastasis

Stage Local, low-gradeConfined perianal mass, low-grade histology — excellent prognosis
Stage Local, high-gradeConfined perianal mass, high-grade histology — worse prognosis
Stage RegionalSublumbar LN metastasis
Stage DistantDistant metastasis (uncommon except high-grade)
Prognostic Factors(3)
Histological gradeLow-grade: MST 1963 days (DFI). High-grade: MST 303 days (DFI). Most critical prognostic factor.(Novel scoring system, Frontiers in Vet Sci 2025)
Tumour sizeTumours >5 cm: 11-fold increased risk of death.
Regional metastasisSublumbar LN metastasis: MST 6-12.5 months for Stage 3-4.
Minimum Workup(6 steps)
1FNA or biopsy of mass (distinguish adenoma from adenocarcinoma)
2Abdominal ultrasound (sublumbar lymph nodes, liver)
3Thoracic radiographs
4Testosterone/hormone panel (if adenoma considered)
5Complete blood count and biochemistry
6Histological grading (low vs high grade — critical for prognosis)

Median Survival Time Comparison

How long the average patient survives with each treatment

Bar opacity reflects evidence strength
Surgical Excision ± Castration
~36 mo (10–65)
Palliation / Antihormonal Therapy
~8 mo (3–14)
Reading this page: MST (Median Survival Time) is how long the average patient survives with a given treatment. ORR (Overall Response Rate) is the percentage of patients whose tumour shrank or disappeared. CR = Complete Response (tumour gone); PR = Partial Response (tumour shrank). Hover over any abbreviation for a quick explanation.
Strength of Evidence

Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.

StrongLarge published studies with strong agreement among veterinary oncologists.
ModerateWidely used in clinical practice, but supported by smaller or retrospective studies.
IndirectEvidence comes from a different tumour type or species and has been applied here.
LimitedVery little published data is available for this specific treatment.

Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.